Octapharma

This article may rely excessively on sources too closely associated with the subject, potentially preventing the article from being verifiable and neutral. Please help by replacing them with more appropriate citations to reliable, independent, third-party sources. (November 2019) (Learn how and when to remove this template message)

Octapharma AG

Type	Private
Industry	Pharmaceutical industry
Founded	1983
Headquarters	Lachen , Switzerland
Number of locations	31
Products	octanate; octanine-F; wilate; Nuwiq; octagam; gammanorm; rhesonativ; panzyga; albunorm; octaplas; atenativ; octaplex; octaplasLG; fibryga See complete products listing.
Revenue	Euro 2.4 billion (2020)[1]
Number of employees	9,067(2020)[2]
Website	www.octapharma.com

Octapharma AG, founded in 1983, is a family-owned pharmaceutical company, and bills itself as "one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines[3]."

Products[]

Patients in 118 countries are treated with products in the following therapeutic areas:

• Haematology: high-purity coagulation factor concentrates for patients with bleeding disorders Haemophilia A, B and von Willebrand Disease.
• Immunotherapy: immunomodulation or immunoglobulin replacement therapy for the treatment of immune-mediated diseases and deficiencies (immune disorders including autoimmune diseases and antibody deficiency) by inducing, enhancing, or suppressing an immune response.
• Critical Care: human plasma and protein products for treating critically ill or injured patients in intensive care and emergency medicine settings.^[3]

History[]

Octapharma was founded in 1983. In the name Octapharma, the “octa” is derived from the Greek word for eight, named after the factor which is deficient in haemophilia A patients. Octapharma’s inaugural product was the first Factor VIII concentrate using what was then innovative solvent detergent virus inactivation technology.

The underlying principle of Octapharma’s R&D is the development of therapies based on human proteins either purified from human plasma or produced by recombinant technologies applied to human cell lines.

Products[]

Octapharma medicines treat a broad range of rare and life-threatening congenital and acquired diseases and conditions:

- bleeding disorders (hemophilia A / B and VWD) - over 300 types of primary and secondary immune deficiencies - numerous auto-immune and neurological disorders - acute conditions - critical care issues (including trauma and burn victims) - cancer patients - major surgeries - protection of new-borns in case of Rh negative pregnancies

Production[]

Octapharma converts source plasma into plasma protein products through fractionation and processing. Each therapy created is controlled, fractionated, purified, virus-inactivated and inspected before being used.

Octapharma owns six production facilities in Austria, France, Germany, Sweden and Mexico, and also 13 plasma donation centres in Europe. Octapharma also owns Octapharma Plasma, which operates 128 donation centers in the United States as of December 2020. Octapharma collects plasma and manufactures it into lifesaving plasma-derived therapies.

Notes and references[]

See also[]

• List of pharmaceutical companies
• Pharmaceutical industry in Switzerland

External links[]

Wikimedia Commons has media related to Octapharma.

• Official website
• Octapharma Plasma, Inc. Website